Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Adge Pharmaceuticals
Mountain View, California, United States
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
Adge Pharmaceuticals is developing elocalcitol (RO269228), an orally available vitamin D receptor agonist small molecule originally developed by Roche, now being evaluated preclinically for obesity, metabolic syndrome, Rett syndrome, and osteogenesis imperfecta; historical clinical data exist in other indications from prior Roche phase 2 studies, but Adge’s current rare-disease and metabolic programs remain preclinical.[1][3][8][13]
- Therapeutic areas
- EndocrinologyNeurologyRare DiseasesMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Cyan Bio
Beyond the preview
Go deeper on Adge Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adge Pharmaceuticals.